Brian G. Feagan, MD

Western University, Canada

Poster(s):

• P2157 - Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P3580 - Impact of Guselkumab Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 12 Results From the Phase 3 QUASAR Induction Study
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT

• P3581 - The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT